Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors - 14/04/20
Doi : 10.1016/j.jaad.2020.02.052
Philip R. Cohen, MD a, b, c, d, ⁎ 
, Razelle Kurzrock, MD e, f
, Razelle Kurzrock, MD e, f a San Diego Family Dermatology, National City, California
b Touro University California College of Osteopathic Medicine, Vallejo, California
c Scripps Family Medicine Residency, Scripps Mercy Hospital Chula Vista, Chula Vista, California
d Family Medicine Residency, Family Health Centers of San Diego, San Diego, California
e Department of Medicine, Division of Hematology/Oncology, University of California San Diego, La Jolla, California
f Center of Personalized Cancer Therapy, University of California San Diego, La Jolla, California
∗Reprint requests: Philip R. Cohen, MD, 10991 Twinleaf Ct, San Diego, CA 92131-364310991 Twinleaf CtSan DiegoCA92131-3643
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Tuesday 14 April 2020
Le texte complet de cet article est disponible en PDF.
| Funding sources: Supported in part by the Joan and Irwin Jacobs Fund and by National Cancer Institute grant P30 CA016672 (to Dr Kurzrock). |
|
| Disclosure: Dr Kurzrock has received research funding from Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols, and Guardant Health; consultant fees from Merck, Pfizer, Roche, X-Biotech, and Actuate Therapeutics; and speaker fees from Roche; holds an ownership interest in CureMatch, Inc; and serves on the Board of CureMatch and CureMetrix, Inc. Dr Cohen has no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?